← Human Trials & Peer-Reviewed Studies
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
Plain-language guide to PMID 15277417 (2004): double-blind randomized controlled trial study of Glucagon and Liraglutide.
Key Facts
- PMID
- 15277417
- Journal
- Diabetes care
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Harder H et al. (4 authors)
- DOI
- 10.2337/diacare.27.8.1915
- Registered trial
- NCT01508949
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Glucagon and Liraglutide.
Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short half-life.
This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic control, body weight, body composition, and 24-h energy expenditure in obese subjects with type 2 diabetes.
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.
Groups ran in parallel: each of the participants stayed in one arm throughout.
In addition to weight and glycemic parameters, body composition was assessed by dual-energy X-ray absorptiometry (DEXA) scanning and 24-h energy expenditure in a respiratory chamber.
What Was Measured
The subject headings attached to it are Blood Glucose, Body Composition, Body Mass Index, Diabetes Mellitus, Type 2, Energy Metabolism, Glucagon and Glucagon-Like Peptide 1.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Liraglutide.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2004 (Diabetes care), a journal based in United States.
More context: the Glucagon compound page and the Liraglutide compound page.
Our Notes on the Compounds
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.